JP2012515775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515775A5 JP2012515775A5 JP2011547964A JP2011547964A JP2012515775A5 JP 2012515775 A5 JP2012515775 A5 JP 2012515775A5 JP 2011547964 A JP2011547964 A JP 2011547964A JP 2011547964 A JP2011547964 A JP 2011547964A JP 2012515775 A5 JP2012515775 A5 JP 2012515775A5
- Authority
- JP
- Japan
- Prior art keywords
- rasagiline
- dosage form
- citrate
- pharmaceutically acceptable
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000245 rasagiline Drugs 0.000 claims description 106
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical group C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims description 105
- 239000002552 dosage form Substances 0.000 claims description 67
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 39
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 239000000454 talc Substances 0.000 claims description 14
- 229910052623 talc Inorganic materials 0.000 claims description 14
- 235000012222 talc Nutrition 0.000 claims description 14
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 229920000881 Modified starch Polymers 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 229960003943 hypromellose Drugs 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 239000004014 plasticizer Substances 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- 239000001069 triethyl citrate Substances 0.000 claims description 7
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 7
- 235000013769 triethyl citrate Nutrition 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 239000006186 oral dosage form Substances 0.000 claims description 5
- 230000000291 postprandial effect Effects 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 206010021518 Impaired gastric emptying Diseases 0.000 claims description 2
- 238000003109 Karl Fischer titration Methods 0.000 claims description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 2
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 2
- 238000009500 colour coating Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000005395 methacrylic acid group Chemical group 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- XJEVHMGJSYVQBQ-SECBINFHSA-N (1r)-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2[C@H](N)CCC2=C1 XJEVHMGJSYVQBQ-SECBINFHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20583309P | 2009-01-23 | 2009-01-23 | |
| US61/205,833 | 2009-01-23 | ||
| US12/456,029 US20100189790A1 (en) | 2009-01-23 | 2009-06-09 | Delayed release rasagiline formulation |
| US12/455,976 | 2009-06-09 | ||
| US12/456,031 US20100189788A1 (en) | 2009-01-23 | 2009-06-09 | Delayed release rasagiline base formulation |
| US12/456,031 | 2009-06-09 | ||
| US12/456,001 | 2009-06-09 | ||
| US12/456,029 | 2009-06-09 | ||
| US12/455,976 US8080584B2 (en) | 2009-01-23 | 2009-06-09 | Delayed release rasagiline citrate formulation |
| US12/456,001 US20100189791A1 (en) | 2009-01-23 | 2009-06-09 | Delayed release rasagiline malate formulation |
| US12/689,044 | 2010-01-18 | ||
| US12/689,044 US7855233B2 (en) | 2009-01-23 | 2010-01-18 | Citrate salt of Rasagiline |
| PCT/US2010/000174 WO2010085354A1 (en) | 2009-01-23 | 2010-01-21 | Delayed release rasagiline formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014239283A Division JP2015091813A (ja) | 2009-01-23 | 2014-11-26 | 遅延放出ラサギリン製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012515775A JP2012515775A (ja) | 2012-07-12 |
| JP2012515775A5 true JP2012515775A5 (enExample) | 2013-03-07 |
| JP5774495B2 JP5774495B2 (ja) | 2015-09-09 |
Family
ID=42354337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011547964A Expired - Fee Related JP5774495B2 (ja) | 2009-01-23 | 2010-01-21 | 遅延放出ラサギリン製剤 |
| JP2014239283A Withdrawn JP2015091813A (ja) | 2009-01-23 | 2014-11-26 | 遅延放出ラサギリン製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014239283A Withdrawn JP2015091813A (ja) | 2009-01-23 | 2014-11-26 | 遅延放出ラサギリン製剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (9) | US20100189791A1 (enExample) |
| EP (3) | EP2381767B1 (enExample) |
| JP (2) | JP5774495B2 (enExample) |
| CN (1) | CN102333442B (enExample) |
| AR (1) | AR075148A1 (enExample) |
| AT (3) | AT12508U1 (enExample) |
| AU (1) | AU2010206970B2 (enExample) |
| CA (3) | CA2727899C (enExample) |
| CY (2) | CY1112486T1 (enExample) |
| CZ (1) | CZ22819U1 (enExample) |
| DE (1) | DE202010017129U1 (enExample) |
| DK (3) | DK2308477T3 (enExample) |
| EA (1) | EA029262B1 (enExample) |
| ES (3) | ES2564317T3 (enExample) |
| HR (2) | HRP20110745T1 (enExample) |
| IL (1) | IL214220A (enExample) |
| PL (2) | PL2246321T3 (enExample) |
| PT (2) | PT2308477E (enExample) |
| RS (2) | RS52421B (enExample) |
| SI (2) | SI2246321T1 (enExample) |
| WO (1) | WO2010085354A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1778196A4 (en) * | 2004-07-26 | 2008-12-17 | Teva Pharma | PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE |
| US20090111892A1 (en) * | 2004-11-24 | 2009-04-30 | Shulamit Patashnik | Rasagiline Orally Disintegrating Compositions |
| EP1991214B1 (en) * | 2006-02-21 | 2015-08-05 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| EP2007369A4 (en) * | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| RS52183B (sr) * | 2006-12-14 | 2012-10-31 | Teva Pharmaceutical Industries, Ltd. | Kristalna čvrsta baza razagilina |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| WO2009032273A1 (en) * | 2007-09-05 | 2009-03-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating glaucoma using rasagiline |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| WO2009089049A1 (en) * | 2008-01-11 | 2009-07-16 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations, their preparation and use |
| US20100008983A1 (en) * | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
| BRPI0909894A2 (pt) * | 2008-06-13 | 2015-07-28 | Teva Pharma | "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica. |
| BRPI0909997A2 (pt) * | 2008-06-19 | 2015-10-27 | Teva Pharma | r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino |
| CA2727021A1 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
| US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| ITPR20090047A1 (it) * | 2009-06-16 | 2010-12-17 | Agricola Cerasaro S S Soc | Procedimento per la produzione di un trito o crema di aglio e trito o crema di aglio cosi' ottenuta |
| DK2451771T3 (da) | 2009-07-09 | 2014-09-08 | Ratiopharm Gmbh | Salte af rasagilin og farmaceutiske fremstillingsmåder heraf |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| AU2010304755A1 (en) * | 2009-10-09 | 2012-05-24 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Progressive Supranuclear Palsy |
| CN102048717B (zh) * | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
| EP2515891A4 (en) * | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-N-propargyl-1-aminoindan |
| WO2012015946A1 (en) | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Dispersion of rasagiline citrate |
| RU2587330C2 (ru) | 2010-07-27 | 2016-06-20 | Тева Фармасьютикал Индастриз Лтд. | Применение разагилина для лечения обонятельной дисфункции |
| MX2013004598A (es) * | 2010-10-26 | 2013-07-17 | Teva Pharma | Rasagilina enriquesida con deuterio. |
| HU231054B1 (hu) * | 2010-11-18 | 2020-04-28 | Egis Gyógyszergyár Nyrt. | Gyógyászati készítmény előállítására alkalmazható új sók |
| PL2665471T3 (pl) | 2011-01-19 | 2018-06-29 | Pathologica, Llc. | Doustne farmaceutyczne postacie dawkowane o kontrolowanym uwalnianiu zawierające mgbg |
| HK1200315A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | R(+)-n-formyl-propargyl-aminoindan |
| JP2014534195A (ja) * | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンシトルアミド |
| HK1200314A1 (en) * | 2011-10-10 | 2015-08-07 | Teva Pharmaceuticals Usa, Inc. | R(+)-n-methyl-propargyl-aminoindan |
| EP2827848B1 (en) | 2012-03-21 | 2016-04-27 | Synthon BV | Stabilized pharmaceutical compositions comprising rasagiline salts |
| US9308182B2 (en) | 2012-08-17 | 2016-04-12 | Teva Pharmaceutical Industries, Ltd. | Parenteral formulations of rasagiline |
| JP2014050039A (ja) * | 2012-09-03 | 2014-03-17 | Sony Corp | 画像処理装置、画像処理方法及びコンピュータプログラム |
| ES2859553T3 (es) | 2013-01-08 | 2021-10-04 | Pathologica Llc | Mitoguazona para el tratamiento de esclerosis múltiple progresiva |
| JP6173098B2 (ja) | 2013-07-30 | 2017-08-02 | キヤノン株式会社 | 光学機器 |
| JP5897196B1 (ja) * | 2015-10-05 | 2016-03-30 | 大同化成工業株式会社 | 糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法 |
| CN107049985B (zh) * | 2017-06-07 | 2020-06-19 | 广州帝奇医药技术有限公司 | 一种抗帕金森病药物的长效缓释制剂及其制备方法 |
| CN109028765A (zh) * | 2018-07-02 | 2018-12-18 | 无锡富泽药业有限公司 | 一种盐酸替罗非班的干燥方法 |
| CN109832262A (zh) * | 2019-01-25 | 2019-06-04 | 袁隆平农业高科技股份有限公司 | 活体植物保存方法 |
| CN114469902B (zh) * | 2020-10-23 | 2024-10-29 | 上海上药中西制药有限公司 | 雷沙吉兰或其药用盐舌下膜剂及其制备方法、应用 |
| CN115400090A (zh) * | 2022-10-09 | 2022-11-29 | 北京新领先医药科技发展有限公司 | 一种雷沙吉兰的口崩片组合物及其制备方法 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US761917A (en) * | 1903-02-11 | 1904-06-07 | Alphonse King | Telegraph-transmitter. |
| US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| IL99759A (en) * | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| IL111240A (en) | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| US5663415A (en) * | 1996-06-28 | 1997-09-02 | Jame Fine Chemicals, Inc. | Process for preparing antihistamine tannates |
| IL118836A (en) * | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| DE69738275T2 (de) * | 1996-12-18 | 2008-08-28 | Teva Pharmaceutical Industries Ltd. | Aminoindanderivate |
| AU6417198A (en) | 1997-03-13 | 1998-09-29 | Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency | Cytoprotective agents comprising monoamine oxidase inhibitors |
| US6548706B2 (en) * | 1999-12-23 | 2003-04-15 | Aerojet Fine Chemicals Llc | Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines |
| DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| US20070197484A1 (en) * | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| EP1390366B1 (en) | 2001-05-14 | 2005-08-31 | Pfizer Products Inc. | The citrate salt of 5,8,14,-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene |
| PY0228255A (es) | 2001-12-06 | 2004-06-01 | Pfizer Prod Inc | Compuestos cristalinos novedosos |
| BR0214780A (pt) | 2001-12-07 | 2004-11-09 | Pfizer Prod Inc | Sal de ácido cìtrico de um composto terapêutico e composições farmacêuticas deste |
| US7118765B2 (en) | 2001-12-17 | 2006-10-10 | Spi Pharma, Inc. | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
| EP1567152B1 (en) | 2002-11-15 | 2013-08-14 | Teva Pharmaceutical Industries Limited | Use of rasagiline with riluzole to treat amyotrophic lateral sclerosis |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| US20060177507A1 (en) * | 2003-05-22 | 2006-08-10 | Joaquina Faour | Controlled release device containing lercanidipine |
| MY144177A (en) | 2004-02-04 | 2011-08-15 | Novartis Ag | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide. |
| US20050214372A1 (en) * | 2004-03-03 | 2005-09-29 | Simona Di Capua | Stable pharmaceutical composition comprising an acid labile drug |
| US7145005B2 (en) | 2004-05-12 | 2006-12-05 | Abbott Laboratories | 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation |
| KR20070036797A (ko) * | 2004-07-26 | 2007-04-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | 장용 코팅된 중심정을 갖는 제형 |
| EP1778196A4 (en) | 2004-07-26 | 2008-12-17 | Teva Pharma | PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE |
| US20060069060A1 (en) | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
| US20090111892A1 (en) | 2004-11-24 | 2009-04-30 | Shulamit Patashnik | Rasagiline Orally Disintegrating Compositions |
| EP1827409B1 (en) | 2004-11-24 | 2011-08-24 | Teva Pharmaceutical Industries, Ltd. | Rasagiline orally disintegrating compositions |
| HRP20130622T1 (en) | 2005-02-17 | 2013-08-31 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| CA2901244A1 (en) | 2005-02-23 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
| US8349951B2 (en) | 2005-05-31 | 2013-01-08 | Prc Desoto International, Inc. | Polythioether polymers and curable compositions containing them |
| US20070078172A1 (en) * | 2005-06-16 | 2007-04-05 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| GB0514593D0 (en) | 2005-07-15 | 2005-08-24 | Davy Process Techn Ltd | Process |
| DE602006008015D1 (de) | 2005-09-19 | 2009-09-03 | Pfizer Prod Inc | Feste salzformen eines pyrrolsubstituierten 2-indolinons |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| JP2009521402A (ja) * | 2005-11-17 | 2009-06-04 | テバ ファーマシューティカル インダストリーズ リミティド | プロパルギル化アミノインダンの分離のための方法 |
| HUP0501084A2 (en) | 2005-11-23 | 2008-05-28 | Richter Gedeon Nyrt | New pharmaceutical compositions of high effectivity |
| US7572834B1 (en) * | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| SA07280004B1 (ar) | 2006-02-02 | 2011-10-29 | استرازينيكا ايه بي | ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات |
| EP1991214B1 (en) * | 2006-02-21 | 2015-08-05 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| JP2009528999A (ja) | 2006-02-21 | 2009-08-13 | アンプラ ファーマシューティカルズ インコーポレイテッド | Ｃｂ１アンタゴニストおよび逆アゴニスト |
| CN101032474B (zh) | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| EP2007369A4 (en) * | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| WO2008010768A1 (en) | 2006-07-17 | 2008-01-24 | Cereuscience Ab | Method of treating and diagnosing restless legs syndrome and periodic limb movements during sleep and means for carrying out the method |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| CN1911211B (zh) * | 2006-08-25 | 2010-04-14 | 重庆医药工业研究院有限责任公司 | 雷沙吉兰口服固体制剂 |
| CN100542524C (zh) * | 2006-09-29 | 2009-09-23 | 北京德众万全药物技术开发有限公司 | 一种含有雷沙吉兰的药用组合物 |
| AR063983A1 (es) | 2006-11-28 | 2009-03-04 | Wyeth Corp | Formulacion de liberacion controlada de agonistas y antagonistas de piperazina -piperidina del receptor 5-ht1a que tienen una disolucion intestinal mejorada |
| RS52183B (sr) | 2006-12-14 | 2012-10-31 | Teva Pharmaceutical Industries, Ltd. | Kristalna čvrsta baza razagilina |
| US8524695B2 (en) * | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
| BRPI0718339A2 (pt) | 2006-12-14 | 2014-02-18 | Teva Pharma | Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina |
| US7949403B2 (en) * | 2007-02-27 | 2011-05-24 | Accelerated Care Plus Corp. | Electrical stimulation device and method for the treatment of neurological disorders |
| US20100130537A1 (en) | 2007-04-26 | 2010-05-27 | Eisai R&D Management Co., Ltd | Cinnamide compounds for dementia |
| EP1987816A1 (de) | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| JP5577012B2 (ja) | 2007-05-03 | 2014-08-20 | 株式会社カネカ | 多層基板およびその製造方法 |
| WO2009032273A1 (en) * | 2007-09-05 | 2009-03-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating glaucoma using rasagiline |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| KR101523195B1 (ko) | 2007-12-24 | 2015-05-27 | 시플라 리미티드 | 프로파길화된 아미노인단 유도체의 합성방법 |
| WO2009089049A1 (en) * | 2008-01-11 | 2009-07-16 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations, their preparation and use |
| US20090247537A1 (en) | 2008-03-25 | 2009-10-01 | William Dale Overfield | Methods for preventing or treating bruxism using dopaminergic agents |
| WO2009122301A2 (en) | 2008-03-31 | 2009-10-08 | Actavis Group Ptc Ehf | Rasagiline mesylate particles and process for the preparation thereof |
| US20100008983A1 (en) * | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
| BRPI0909894A2 (pt) | 2008-06-13 | 2015-07-28 | Teva Pharma | "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica. |
| BRPI0909997A2 (pt) * | 2008-06-19 | 2015-10-27 | Teva Pharma | r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino |
| CA2727021A1 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
| CN101606923B (zh) | 2008-06-20 | 2013-01-09 | 重庆医药工业研究院有限责任公司 | 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法 |
| EA201170181A1 (ru) | 2008-07-11 | 2011-08-30 | Синтон Бв | Полиморфные формы разагилина гидрохлорида |
| AR074637A1 (es) | 2008-07-18 | 2011-02-02 | Medichem Sa | Formas de sal de adicion acida de r-(+)-n-propargil-1-aminoindano (es decir , base de rasagilina), un compuesto de formula (1), procesos para prepararlos y aislarlos y usos de los mismos |
| US20100029987A1 (en) * | 2008-07-29 | 2010-02-04 | Dipharma Francis S.R.I. | Crystalline Form of Rasagiline and Process for the Preparation Thereof |
| WO2010013048A1 (en) | 2008-07-30 | 2010-02-04 | Generics [Uk] Limited | Polymorphic form of rasagiline mesylate |
| EP2181980A1 (en) | 2008-10-28 | 2010-05-05 | Chemo Ibérica, S.A. | A process for the preparation of (R)-1-aminoindanes |
| DE102008064061A1 (de) | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
| US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| DK2451771T3 (da) * | 2009-07-09 | 2014-09-08 | Ratiopharm Gmbh | Salte af rasagilin og farmaceutiske fremstillingsmåder heraf |
| EP2456750A2 (en) | 2009-07-20 | 2012-05-30 | Medichem, S.A. | New form of the aminoindan mesylate derivative rasaginline mesylate |
| WO2011010324A1 (en) | 2009-07-23 | 2011-01-27 | Alkem Laboratories Ltd. | Oral pharmaceutical composition of rasagiline and process for preparing thereof |
| AU2010304755A1 (en) * | 2009-10-09 | 2012-05-24 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Progressive Supranuclear Palsy |
| CN102048717B (zh) * | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
| EP2515891A4 (en) | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-N-propargyl-1-aminoindan |
-
2009
- 2009-06-09 US US12/456,001 patent/US20100189791A1/en not_active Abandoned
- 2009-06-09 US US12/456,029 patent/US20100189790A1/en not_active Abandoned
- 2009-06-09 US US12/456,031 patent/US20100189788A1/en not_active Abandoned
- 2009-06-09 US US12/455,976 patent/US8080584B2/en not_active Expired - Fee Related
-
2010
- 2010-01-18 US US12/689,044 patent/US7855233B2/en not_active Expired - Fee Related
- 2010-01-21 US US13/145,989 patent/US20120003310A1/en not_active Abandoned
- 2010-01-21 EA EA201170962A patent/EA029262B1/ru not_active IP Right Cessation
- 2010-01-21 CA CA2727899A patent/CA2727899C/en not_active Expired - Fee Related
- 2010-01-21 CA CA2799515A patent/CA2799515A1/en not_active Abandoned
- 2010-01-21 AU AU2010206970A patent/AU2010206970B2/en not_active Ceased
- 2010-01-21 JP JP2011547964A patent/JP5774495B2/ja not_active Expired - Fee Related
- 2010-01-21 EP EP10733731.3A patent/EP2381767B1/en active Active
- 2010-01-21 ES ES10733731.3T patent/ES2564317T3/es active Active
- 2010-01-21 CN CN201080009551.4A patent/CN102333442B/zh not_active Expired - Fee Related
- 2010-01-21 CA CA2713292A patent/CA2713292C/en not_active Expired - Fee Related
- 2010-01-21 WO PCT/US2010/000174 patent/WO2010085354A1/en not_active Ceased
- 2010-01-22 RS RS20120337A patent/RS52421B/sr unknown
- 2010-01-22 PL PL10166534T patent/PL2246321T3/pl unknown
- 2010-01-22 ES ES10166534T patent/ES2370980T3/es active Active
- 2010-01-22 SI SI201030008T patent/SI2246321T1/sl unknown
- 2010-01-22 RS RS20110487A patent/RS52033B/sr unknown
- 2010-01-22 AT ATGM76/2011U patent/AT12508U1/de not_active IP Right Cessation
- 2010-01-22 EP EP10186379A patent/EP2308477B1/en active Active
- 2010-01-22 PL PL10186379T patent/PL2308477T3/pl unknown
- 2010-01-22 EP EP10166534A patent/EP2246321B1/en active Active
- 2010-01-22 PT PT10186379T patent/PT2308477E/pt unknown
- 2010-01-22 DK DK10186379.3T patent/DK2308477T3/da active
- 2010-01-22 DE DE202010017129U patent/DE202010017129U1/de not_active Expired - Lifetime
- 2010-01-22 PT PT10166534T patent/PT2246321E/pt unknown
- 2010-01-22 AR ARP100100139A patent/AR075148A1/es unknown
- 2010-01-22 DK DK10166534.7T patent/DK2246321T3/da active
- 2010-01-22 SI SI201030050T patent/SI2308477T1/sl unknown
- 2010-01-22 AT AT10166534T patent/ATE518527T1/de active
- 2010-01-22 AT AT10186379T patent/ATE556703T1/de active
- 2010-01-22 ES ES10186379T patent/ES2389889T3/es active Active
-
2011
- 2011-01-27 CZ CZ201123855U patent/CZ22819U1/cs not_active IP Right Cessation
- 2011-03-11 DK DKBA201100050U patent/DK201100050U4/da not_active IP Right Cessation
- 2011-07-20 IL IL214220A patent/IL214220A/en not_active IP Right Cessation
- 2011-10-13 HR HR20110745T patent/HRP20110745T1/hr unknown
- 2011-10-31 CY CY20111101033T patent/CY1112486T1/el unknown
- 2011-12-23 US US13/336,609 patent/US20120100189A1/en not_active Abandoned
-
2012
- 2012-06-29 US US13/538,715 patent/US20120263789A1/en not_active Abandoned
- 2012-07-31 CY CY20121100679T patent/CY1112954T1/el unknown
- 2012-08-02 HR HRP20120633AT patent/HRP20120633T1/hr unknown
-
2013
- 2013-12-23 US US14/139,212 patent/US20140186514A1/en not_active Abandoned
-
2014
- 2014-11-26 JP JP2014239283A patent/JP2015091813A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2713292A1 (en) | Delayed release rasagiline formulation | |
| CN101534792B (zh) | 包含氧可酮的粒剂和口腔崩解片剂 | |
| JP2011509295A5 (enExample) | ||
| AU2011290614B2 (en) | Nalbuphine-based formulations and uses thereof | |
| CN1358090A (zh) | 左旋多巴/卡比多巴/恩他卡朋药物制剂 | |
| JP2013537530A5 (enExample) | ||
| CN102724970A (zh) | 来那替尼马来酸盐的片剂制剂 | |
| JP7336388B2 (ja) | 錠剤及びその製造方法 | |
| MX2010008711A (es) | Composiciones farmaceuticas de entacapona, levopoda y carbidopa, con biodisponibilidad mejorada. | |
| TW201038300A (en) | Galenic formulations of organic compounds | |
| EA014707B1 (ru) | Новая форма введения рацекадотрила | |
| BRPI0614021A2 (pt) | formulações farmacêuticas e métodos de uso | |
| US20250120935A1 (en) | Compositions of triglycerides and uses thereof | |
| CN112449601B (zh) | 含纳呋拉啡口腔崩解片 | |
| WO2009000132A1 (fr) | Formulation effervescente à libération immédiate et procédé de préparation de celle-ci | |
| JP2020536931A5 (enExample) | ||
| JP2025506890A (ja) | 治療用の化合物、製剤、およびそれらの使用 | |
| KR20000015865A (ko) | 칼륨, 나트륨 및 트리스옥사프로진염의 약학적 제제 | |
| CN101700245A (zh) | 一种治疗感冒的复方药物及其制备工艺 | |
| JP6216408B2 (ja) | 固体剤形で非常に難溶性の薬物を調製する方法 | |
| CN1173698C (zh) | 包含包衣的雷尼替丁、碱式柠檬酸铋和硫糖铝的对胃肠障碍具有治疗作用的可口服给药的药物制剂 | |
| US20160287651A1 (en) | Solid preparations containing pelargonium sidoides extracts and silicic acid compound, and preparing method thereof | |
| WO2011081118A1 (ja) | 経口投与用医薬組成物 | |
| KR101428149B1 (ko) | 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법 | |
| CN105012247A (zh) | 一种二乙酰大黄酸组合物及其制备方法 |